Soleno Therapeutics, Inc. (NASDAQ:SLNO) Receives Consensus Rating of "Hold" from Analysts

Key Points

• Analysts have assigned Soleno an average rating of Hold from 13 analysts (1 sell, 9 hold, 3 buy) with a mean 12‑month price target of $76.67, and several recent downgrades have pushed some targets into the low $50s.
• The company posted a quarterly beat (<$strong>0.80 EPS vs. $0.64 expected; $91.7M revenue vs. $88.6M expected) and projects ~3.67 EPS for the year, but the shares trade at a high PE (~230) and have shown wide volatility (52‑week range $29.43–$90.32).
• Multiple securities‑fraud class‑action notices have been filed for the Mar. 26–Nov. 4, 2025 period with a May 5, 2026 lead‑plaintiff deadline, creating potential legal exposure that could pressure the stock.

Shares of Soleno Therapeutics, Inc. (NASDAQ:SLNO - Get Free Report) have been assigned an average rating of "Hold" from the thirteen analysts that are presently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, nine have given a hold recommendation and three have issued a buy recommendation on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $76.6667.

SLNO has been the topic of a number of analyst reports. Wolfe Research cut shares of Soleno Therapeutics from an "outperform" rating to a "hold" rating in a research note on Tuesday, April 7th. Robert W. Baird cut shares of Soleno Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 6th. Cantor Fitzgerald downgraded shares of Soleno Therapeutics from an "overweight" rating to a "hold" rating and lowered their price target for the stock from $123.00 to $53.00 in a report on Monday, April 6th. Wells Fargo & Company set a $53.00 price objective on shares of Soleno Therapeutics and gave the company an "equal weight" rating in a report on Friday, April 17th. Finally, Wall Street Zen downgraded shares of Soleno Therapeutics from a "buy" rating to a "hold" rating in a research report on Sunday, March 22nd.

Soleno Therapeutics Stock Performance

Shares of SLNO stock opened at $52.90 on Tuesday. The stock has a market cap of $2.73 billion, a PE ratio of 230.01 and a beta of -2.22. The business has a 50-day simple moving average of $42.46 and a 200-day simple moving average of $46.65. The company has a quick ratio of 5.55, a current ratio of 5.80 and a debt-to-equity ratio of 0.11. Soleno Therapeutics has a 52-week low of $29.43 and a 52-week high of $90.32.

Soleno Therapeutics (NASDAQ:SLNO - Get Free Report) last posted its earnings results on Wednesday, February 25th. The company reported $0.80 EPS for the quarter, topping the consensus estimate of $0.64 by $0.16. The company had revenue of $91.73 million for the quarter, compared to analyst estimates of $88.55 million. On average, equities analysts expect that Soleno Therapeutics will post 3.67 EPS for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in SLNO. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Soleno Therapeutics by 1.1% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 17,360 shares of the company's stock valued at $1,242,000 after acquiring an additional 189 shares during the period. Goldman Sachs Group Inc. lifted its holdings in Soleno Therapeutics by 50.9% during the first quarter. Goldman Sachs Group Inc. now owns 633,110 shares of the company's stock valued at $45,236,000 after purchasing an additional 213,667 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in Soleno Therapeutics by 48.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 40,715 shares of the company's stock valued at $2,909,000 after purchasing an additional 13,211 shares in the last quarter. Creative Planning acquired a new stake in shares of Soleno Therapeutics in the second quarter valued at about $338,000. Finally, Prudential Financial Inc. purchased a new stake in shares of Soleno Therapeutics during the second quarter worth about $413,000. 97.42% of the stock is owned by institutional investors and hedge funds.

More Soleno Therapeutics News

Here are the key news stories impacting Soleno Therapeutics this week:

• Positive Sentiment: Quarterly fundamentals support valuation — Soleno reported $0.80 EPS vs. $0.64 expected and $91.7M revenue vs. $88.6M expected on Feb. 25, suggesting continued commercial progress and giving investors a fundamental reason to hold or buy. (Background: company beat analyst estimates and forecasts ~3.67 EPS for the year.)
• Neutral Sentiment: Lead‑plaintiff deadline reminder — multiple law firms are reminding purchasers of SLNO between March 26, 2025 and November 4, 2025 of the May 5, 2026 deadline to seek lead‑plaintiff status; this is procedural but concentrates attention on the pending litigation timeline. ROSEN: Deadline Tomorrow
• Negative Sentiment: Multiple securities‑fraud class action notices and filings have been published by national plaintiff firms alleging violations tied to the March 26–Nov 4, 2025 class period; firms actively soliciting clients include Bragar Eagel & Squire, Rosen, Faruqi & Faruqi, Bronstein Gewirtz & Grossman, Hagens Berman, DJS Law Group, Schall Law Firm, and others — increased legal exposure and potential damages or settlements could pressure SLNO’s share price and increase volatility. Bragar Eagel & Squire Notice Faruqi & Faruqi Notice Bronstein Gewirtz & Grossman Notice Hagens Berman Notice PR Newswire / Rosen DJS Law Group Notice Schall Law Firm Notice

About Soleno Therapeutics

Soleno Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development and commercialization of therapies for rare and orphan diseases. Headquartered in Redwood City, California, Soleno leverages a precision medicine approach to identify and advance small‐molecule treatments that address underlying genetic and metabolic dysfunctions. The company's scientific strategy centers on repurposing and reformulating existing compounds to maximize therapeutic benefit in underserved patient populations.

The company's lead candidate, diazoxide choline controlled release (DCCR), is being investigated for the treatment of Prader-Willi syndrome (PWS), a complex neurodevelopmental disorder characterized by insatiable appetite, hormonal imbalances and behavioral challenges.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.